Genocea to Host Second Quarter 2018 Financial Results Conference Call & Webcast on August 2, 2018 at 9:00 a.m. ET
Interested participants may access the conference call by dialing (800) 347-6311 (domestic) or (323) 994-2131 (international) and referring to conference ID number 3544411. To join the live webcast, please visit the investor relations section of the Genocea website at http://ir.genocea.com.
A webcast replay will be available on the Genocea website beginning approximately two hours after the event and will be archived for 90 days.
Genocea's mission is to help conquer cancer through targeted vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is using ATLAS to develop neoantigen cancer vaccines and early stage programs targeting tumor-associated antigens and cancers caused by Epstein-Barr Virus. Genocea is currently studying the safety, immunogenicity, and efficacy of its lead neoantigen cancer vaccine, GEN-009, in a Phase 1/2a clinical trial. For more information, please visit www.genocea.com.
Source: Genocea Biosciences, Inc.